Blood test monitoring on Mounjaro: what gets checked and why

Step 1, baseline bloods: what a prescriber wants to see before treatment

Before tirzepatide is prescribed, a prescriber builds a clinical picture of your metabolic health. For many patients starting Mounjaro, a baseline blood panel gives that foundation. The tests most commonly ordered at this stage cover fasting glucose or HbA1c (to establish where blood sugar sits before a medicine that actively lowers it), a lipid profile (total cholesterol, LDL, HDL, triglycerides), liver function, and kidney function via eGFR and creatinine. Thyroid function may be added if there is a clinical reason.

Why does this baseline matter? Because tirzepatide changes several of these numbers during treatment, sometimes quite noticeably. A reading taken six months in only tells you where things are now; a baseline reading tells you how far they have moved and in which direction. That context shapes clinical decisions about dose, duration and any additional support you might benefit from. The Mounjaro prescribing page explains the broader eligibility picture if you want to read around this.

If you are transferring from another provider or have recent bloods from your GP, your prescriber may use those rather than repeating tests unnecessarily. Recent results are evidence, and good prescribers work with what exists rather than running tests for the sake of it.

Step 2 (on-treatment monitoring: the checkpoints that matter most

Once treatment is underway, the monitoring schedule is not rigid) it adapts to you. A person who started at 2.5mg with no pre-existing metabolic conditions and no symptoms needs a different approach from someone with type 2 diabetes or raised liver enzymes at baseline. What prescribers typically watch for during treatment falls into a few categories.

Blood glucose and HbA1c are the most clinically active. Tirzepatide has a meaningful glucose-lowering effect (that is partly why it is also licensed for type 2 diabetes) and in people who are not diabetic, blood sugar can drop more than expected, particularly if other medicines are involved. Liver function is worth rechecking because significant weight loss, even when entirely healthy, can cause transient changes in LFT readings as the liver processes redistributed fat. Kidney markers round out the routine picture: the GI side effects of tirzepatide (nausea, vomiting, reduced appetite) can reduce fluid intake, which in turn affects kidney function transiently if dehydration takes hold.

A question our prescribers hear most weeks is whether blood tests at the GP are still necessary once treatment is running smoothly. The short answer is yes, your GP remains your long-term clinician, and keeping them in the loop, including with any blood results, is part of responsible care. Ongoing Mounjaro monitoring covers this territory in more detail.

Step 3, reading the results: what changes are expected versus what warrants a call

Some shifts in blood results on tirzepatide are expected, even positive. Clinical trial data published in the SURMOUNT-1 paper in the New England Journal of Medicine showed improvements in HbA1c, triglycerides and LDL cholesterol alongside the weight reduction. If your next blood test shows meaningfully better lipid or glucose readings, that is consistent with how the medicine works, not a cause for concern.

What does warrant attention? A sustained rise in liver enzymes beyond the early transient pattern, a significant drop in kidney function, or blood sugar readings running unusually low all deserve a conversation with your prescriber. Severe, persistent stomach pain that radiates to the back is a separate, more urgent signal: the MHRA's Yellow Card scheme exists precisely for suspected serious reactions, and acute pancreatitis, though infrequent, was the subject of the MHRA's January 2026 Drug Safety Update on GLP-1 medicines. Anyone experiencing that symptom pattern should get same-day medical help rather than waiting for a routine call.

For a deeper read on what tirzepatide does and does not show in standard blood panels (including whether it appears as a flagged substance) the dedicated page on Mounjaro and blood test results covers that question specifically. There is also a useful overview of tirzepatide and blood test interactions if you are preparing for pre-op or occupational health screening.

Step 4, practical logistics: getting blood tests done alongside private treatment

Private Mounjaro treatment and NHS blood testing can run in parallel. Your GP can order standard metabolic panels on the NHS; you do not need private bloods simply because your prescription is private. Telling your GP that you are taking tirzepatide, and sharing your treatment provider's contact details, means they can factor it into any results they review. Some GP practices receive a notification from the prescribing pharmacy as a matter of course, at nume, GP notification is a standard part of the clinical process in line with GPhC guidance, not an optional extra.

If you are self-funding blood tests, several accredited private labs offer the core metabolic panel for a reasonable fixed fee. The Mounjaro blood tests page sets out the options and what each test is actually measuring, which makes the lab menu far less confusing. For background on private treatment costs more broadly, the weight-loss treatments page is the clearest starting point.

Worth knowing: the NHS tirzepatide medicines page lists interactions and monitoring considerations that apply equally in private settings, it is written for patients and is a reliable reference when you want to check something between appointments. If you have specific questions about your own results or symptoms, our team is available seven days a week.